Gene Therapy for Liver Tumours

  • Ragai R. Mitry
  • Marc R. Mansour
  • Roman Havlik
  • Nagy A. Habib
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 465)

Keywords

Gene Therapy Thymidine Kinase Colorectal Liver Metastasis Bystander Effect Cancer Gene Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allgaier, H.P., Deibert, P., Becker, G., and Blum, H.E., 1998, Hepatocellular carcinoma: non-surgical treatment. Schweiz Rundsch Med Prax 87:1466–1470.PubMedGoogle Scholar
  2. Anderson, W.F., 1984, Prospects for human gene therapy. Science 226:401–409.PubMedGoogle Scholar
  3. Anderson, S.C, Johnson, D.E., Harris M.P., Engler, H., Hancock, W., Huang, W.-M., Wills, K.N., Gregory, R.J., Sutjipto, S., Wen, S.F., Lofgren, S., Shepard, H.M., and Maneval, D.C., 1998, p53 Gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of recombinant adenovirus. Clin. Cancer Res. 4:1649–1659.PubMedGoogle Scholar
  4. Baba, M., Yamamoto, R., Iishi, H., and Tatsuta, M., 1997, Ha-ras mutations in N-nitrosomorpholine-induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver. Int. J. Cancer 72:815–820.PubMedCrossRefGoogle Scholar
  5. Barisani, D., Green. R.M., and Gollan, J.L., 1999, Genetic hemochromatosis: pathogenesis, diagnosis, and therapy. Dig. Dis. 14(15):304–315.Google Scholar
  6. Bishop, J.M., 1987, The molecular genetics of cancer. Science 235:305–311.PubMedGoogle Scholar
  7. Bishop, J.M., 1986, Oncogenes and proto-oncogenes. J. Cell Physiol, suppl 4:1–5.Google Scholar
  8. Blumgart, L.H., and Fong, Y. 1995, Surgical options in the treament of hepatic metastases from colorectal cancer. Curr. Probl. Surg. 32:333–428.PubMedGoogle Scholar
  9. Bressac, B., Galvin, K.M., Liang, T.J., Isselbacher, K.J., Wands, J.R., and Ozturk, M., 1990, Abnormal strusture and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87:1973–1977.PubMedGoogle Scholar
  10. Bressac, B., Kew, M., Wands, J., and Ozturk, M., 1991, Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431.PubMedCrossRefGoogle Scholar
  11. Carr, B.I., Flickinger, J.C., and Lotze, M.T. Hepatobiliary Cancers. In: DeVita VT, Jr. Hellman S, Rosenberg SA. eds. Cancer Principles and Practice of Oncology. 5th ed. Philadelphia: J.B. Lippincott Co., 1997:1087–1114.Google Scholar
  12. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann J.L., and Klatzmann, D., 1993, Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90:7024–7028.PubMedGoogle Scholar
  13. Caselmann, WH., 1995, Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J. Hepatol. 21:34–37.Google Scholar
  14. Crystal, R.G., 1997, Phase I study of direct administration of a replication deficient adenovirus vector containing E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Theapy 8:985–1001.Google Scholar
  15. Curley, S.A., and Vecchio, R., 1998, New trends in the surgical treatment of colorectal cancer liver metastases. Tumori 84:281–288.PubMedGoogle Scholar
  16. Dourakis, S.P., and Tolis, G., 1998, Sex hormonal preparations and the liver. Eur. J. Contracept. Reprod. Health Care 3(1):7–16.PubMedCrossRefGoogle Scholar
  17. Eagon, P.K., Elm, M.S., Epley, M.J., Shinozuka, H., and Rao, K.N., 1996, Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroentrol 110(4):1199–1207.Google Scholar
  18. Fellows, I.W., Stewart, M., Jeffcoate, W.J., Smith, P.G., and Toghill, P.J., 1988, Hepatocellular carcinoma in primary hemochromatosis in the abscence of cirrhosis. Gut,29, 1603–1606.PubMedGoogle Scholar
  19. Finlay, C.A., Hinds, P.W., and Levine, A.J., 1989, The p53 proto-oncogene can act as a suppressor of transformation. Cell 57(7):1083–1093.PubMedCrossRefGoogle Scholar
  20. Fong, Y., and Blumgart, L.H., 1998, Hepatic colorectal metastasis: current status of surgical therapy. Oncology 12:1489–98.PubMedGoogle Scholar
  21. Freeman, S.M. Therapeutic Applications of HSV-TK Suicide Gene. 3rd International Cancer Gene Therapy Meeting, Imperial College School of Medicine. May 1998.Google Scholar
  22. Freeman, S., Abboud, C., Whartenby, K.., Packman, C., Moolten, F., and Abraham, G., 1993, The “bystander effect”, tumour regression when a fraction of the tumour mass is genetically modified. Cancer Research 53:5274–5283.PubMedGoogle Scholar
  23. Gerber, M.A., 1995, Pathobiological effects of hepatitis C. J. Hepatol. 22:83–86.PubMedGoogle Scholar
  24. Gerbes, A.L., and Caselmann, W.H., 1993, Point mutations of the p53 gene, human hepatocellular carcinoma and aflatoxins. J. Hepatol. 19:312–315.PubMedCrossRefGoogle Scholar
  25. Gou, Y. Cytokines and Immunotherapy. In: Mazarakis H, Swart SJ., eds. Cancer Gene Therapy. MA: IBC, 1997:155–168.Google Scholar
  26. Gundlach, M., Brunken, C., Broelsch, C.E., 1998, Hepatocellular carcinoma: surgical treatment. Schweiz Rundsch Med Prax 87:1471–1474.PubMedGoogle Scholar
  27. Habib, N.A., Ding, S.-F., El-Masry, R., Mitry, R.R., Honda, K., Michail, N.E., Dalla Serra, G., Izzi, G., Greco, L., Bassyouni, M., El-Toukhy M., and Abdel-Gaffar, Y., 1996, Preliminary Report: The short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detection and Prevention 20:103–107.PubMedGoogle Scholar
  28. Harris, M.P., Sutjipto, S., Wills, K.N., Hancock, W., Cornell, D., Johnson, D.E., Gregory, R.J., Shepard, H.M., and Maneval, D.C., 1996, Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 3(2):121–30.PubMedGoogle Scholar
  29. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C., 1991, p53 Mutations in Human Cancers. Science 253:49–53.PubMedGoogle Scholar
  30. Honda, K., Sbisa, E., Tullo, A., Papeo, P.A., Saccone, C., Poole, S., Pignatelli, M., Mitry, R.R., Ding, S., Isla, A., Davies, A., and Habib, N.A., 1998, p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br. J. Cancer 1998, 77(5):776–782.PubMedGoogle Scholar
  31. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., and Nagataki, S., 1995, Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55:3105–3109.PubMedGoogle Scholar
  32. Jiao, R.L., Hansen, P.D., Havlik, R., Mitry, R.R., Pignatelli, M., and Habib, N.A., 1999, Clinical short-term results of radiofrequency ablation in primary and secondary liver tumours. Am. J. Surg. [Accepted].Google Scholar
  33. Jolly, D., 1994, Viral vector systems for gene therapy. Cancer Gene Therapy 1:51–64.PubMedGoogle Scholar
  34. Kanai, F., Hamada, H., Shiratori, Y., and Omata, M., 1997, Adenovirus-mediated enzyme-prodrug therapy for cancer. The Cancer Journal 10(6) [Novermber/December].Google Scholar
  35. Kanai, F., Lan, K.H., Shiratori, Y., Tanaka, T., Ohashi, M., and Omata, M., 1997, In vivo gene therapy for alpha-fetoprotein—producing hepatocellular carcinoma by adenovirus-mediatd transfer of cytosine deaminase gene. Cancer Res. 57(3):461–465.PubMedGoogle Scholar
  36. Kanai, F., Shiratori, Y., Yoshida, Y., Kanegae, Y., Nakabayashi, H., and Omata, M., 1996, Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 23:1359–1367.PubMedGoogle Scholar
  37. Kanazawa, Y. Antisense Approach. In: Mazarakis H, Swart SJ., eds. Cancer Gene Therapy. MA: IBC, 1997:223–231.Google Scholar
  38. Kanazawa, Y., Ohkawa, K., Ueda, K., Mita, E., Takehara, T., and Hayashi, N., 1996, Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225(2):570–576.PubMedCrossRefGoogle Scholar
  39. Kato, I., and Kido, C., 1987, Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn. J. Cancer Res. 78(11):1187–1192.PubMedGoogle Scholar
  40. Kew, M.C., 1996, The hepatitis B virus and the genesis of hepatocellular carcinoma. G. I. Cancer 1:143–148.Google Scholar
  41. Kishimoto, K., Fujimoto, J., Takeuchi, M., Yamamoto, H., Ueki, T., and Okamoto, E., 1998, Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J. Surg. Oncol. 69(3):119–24. Ko, L.J., Prives, C., 1996, p53: puzzle and paradigm. Genes Dev. 10(9):1054-1072.PubMedCrossRefGoogle Scholar
  42. Kobertz, W.R., Wang, D., Wogan, G.N., and Essigmann, J.M., 1997, An intercalation inhibitor altering the target selectivity of DNA damaging agents: synthesis of site-specific alflatoxin B1 adducts in a p53 mutational hotspot. Proc. Natl. Acad. Sci. USA 94(18):9579–9584.PubMedCrossRefGoogle Scholar
  43. Kuriyama, S., Masui, K., Sakamoto, T., Nakatani, T., Kikukawa, M., and Tsujii, T., 1998, Bystander effect caused bu cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Research 18(5A):3399–406.PubMedGoogle Scholar
  44. Lane, D.P., 1992, p53, guardian of the genome. Nature 358, 15–16.PubMedCrossRefGoogle Scholar
  45. Liao, Y., Tang, Z.Y., Liu K.D., Ye, S.L., and Huang, Z., 1997, Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA—in vitro and in vivo studies. J. Cancer. Res. Clin. Oncol. 123(1):25–33.PubMedCrossRefGoogle Scholar
  46. Livraghi, T., Vettori, C., and Lazzaroni, S., 1991, Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 179:709–712.PubMedGoogle Scholar
  47. Lunn, R.M., Zhang, Y.-J., Wang, L.-Y., Chen, C.-J., Lee, P.-H., Lee, C.-S., Tsai, W.Y., and Santella, R.M., 1997, p53 mutations, chronic Hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 57:3471–3477.PubMedGoogle Scholar
  48. Lygidakis, N.J., Kosmidis, P., Yiras, N., Parissis, J., Kyparidou, E., 1995, Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 15:467–472.PubMedCrossRefGoogle Scholar
  49. Marone, G., Francica, G., D’Angelo, V., Iodice, G., Pastore, P., and Siani, A., 1998, Echo-guided radiofrequency percutaneous ablation of hepatocellular carcinoma in cirrhosis using a cooled needle. Radiol Med 95:624–629.PubMedGoogle Scholar
  50. Mitry, R.R., Sarraf, C.E., Wu, C.G., Pignatelli, M., and Habib, N.A., 1997, Wild-type p53 induces apoptosis in Hep3B through up-regulation of bax expression. Lab. Invest. 1997, 77(4):369–378.PubMedGoogle Scholar
  51. Moolten, F.L., and Wells, J.M., 1990, Curability of tumours bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82:297–300.PubMedGoogle Scholar
  52. Moolten, F.L., 1986, Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res.; 46:5276–5281.PubMedGoogle Scholar
  53. Nagashima, I., Hamada, C., and Naruse, K., 1996, Surgical resection for small hepatocellular carcinoma. Surgery 119:40–45.PubMedGoogle Scholar
  54. Nakabayashi, H., Watanabe, K., Saito, A., Otsuru, A., Sawadaishi, K., and Tamaoki, T., 1989, Transcriptional regulation of alpha-fetoprotein expression by dexamethasone in human hepatoma cells. J. Biol. Chem. 264:266–271.PubMedGoogle Scholar
  55. Oda. T., Tsuda, H., Sakamoto, M., and Hirohashi., S., 1994, Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett. 83(1–2):197–200.PubMedGoogle Scholar
  56. Ohta, Y., Kijima, H., Ohkawa, T., Kashani-Sabet, M., and Scanlon, K.J., 1996, Tissue specific expression of an anti-ras ribozyme inhibits proliferation of human malignant cells. Nuc. Acids Res. 24(5): 938–942.Google Scholar
  57. Olajos, E.J., 1977, Biological interactions of N-nitroso compounds: a review. Ecotoxicol. Environ. Safety 1:175–196.PubMedCrossRefGoogle Scholar
  58. Philosophe, B., Greig, P.D., Hemming, A.W., Cattral, M.S., and Langer, B., 1998, surgical management of hepatocellular carcinoma: resection or transplantation? J Gastrointestinal Surg 2:21–27.Google Scholar
  59. Puisieux, A., Galvin, K., Troalen, F., Bressac, B., Marcais, C., Galun, E., Ponchel, F., Yakicier, C., Ji, J., and Ozturk, M., 1993a, retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 7:1407–1413.PubMedGoogle Scholar
  60. Puisieux, A., Ponchel, F., and Ozturk, M., 1993b, p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 8:487–490.PubMedGoogle Scholar
  61. Roth, J.A., and Cristiano, R.J., 1997, Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89:21–39.Google Scholar
  62. Rougier, P., 1998, Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? The case of liver metastases from colorectal cancer. Recent Results Cancer Res 147:3–12.PubMedGoogle Scholar
  63. Scanlon, K. Antisense Approach. In: Mazarakis H, Swart SJ., eds. Cancer Gene Therapy. MA: IBC, 1997:197–212.Google Scholar
  64. Scorsone, K.A., Zhou, Y.-Z., Butel, J.S., and Slagle, B.L., 1992, p53 Mutations Cluster at Codon 249 in Hepatitis B Virus-positive Hepatocellular Carcinomas from China. Cancer Res. 52:1635–1638.PubMedGoogle Scholar
  65. Seitz, H.K., Poschl, G., and Simanowski, U.A., 1998, Alcohol and cancer. Recent. Dev. Alcohol 14:67–95.PubMedGoogle Scholar
  66. Sheiner, P.A., Brower, S.T., Treatment of metastatic cancer to the liver. Sem Liver Dis 1994, 14:169–177.CrossRefGoogle Scholar
  67. Sheu, J.C., Huang, G.T., Lee, P.H., Chung, J.C., Chou, H.C., Lai, M.Y., Wang, J.T., Lee, H.S., Shih, L.N., Yang, P.M., et al., 1992, Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 52(21):6098–6100.PubMedGoogle Scholar
  68. Solomon. E., Borrow. J., and Goddard, A.D., 1991, Chromosome aberrations and cancer. Science 254:1153–1160.PubMedGoogle Scholar
  69. Spitz, F.R., Nguyen, D., Skibber, J.M., Cusack, J., Roth, J.A., and Cristiano, R.J., 1996, In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16:3415–22.PubMedGoogle Scholar
  70. Steele, G., Standard postoperative monitoring of patients after resection of colon and rectum cancer. Cancer, 1993; 71;1993.Google Scholar
  71. Su, H., Chang, J., Mei Xu, S., and Wai Kan, Y., 1996, Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Therapy 7:463–470.Google Scholar
  72. Tabor, E., 1994, Tumor suppressor genes, growth factor genes, and oncogenes in Hepatitis B virus-associated hepatocellular carcinoma. J. Med. Virol. 42:357–365.PubMedGoogle Scholar
  73. Tahara, H., Nakanishi, T., Kitamoto, M., Nakashio, R., Shay, J.W., and Ide, T., 1995, Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 55(13):2734–6.PubMedGoogle Scholar
  74. Tiraby, M., Cazaux, C., Baron, M., Drocourt, D., Reynes, J.P., and Tiraby, G., 1998, Concomitant expression of E.coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotxicity of 5-fluorocytosine. FEMS Microbiol. Lett. 167(1):41–49.PubMedCrossRefGoogle Scholar
  75. Ueki, T., Nakata, K., Mawatara, F., Tsuruta, S., Ido, A., and Eguchi, K., 1998, Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice. Int. J. Mol. Med. 1(4):671–675.PubMedGoogle Scholar
  76. Vaughn, D.J., Haller, D.G., 1993 Nonsurgical management of recurrent colorectal cancer. Cancer, 71: 4278–4292.PubMedGoogle Scholar
  77. Vogelstein, B., and Kinzler, K.W., 1993, The multistep nature of cancer. TIG 9(4):138–141.PubMedGoogle Scholar
  78. Wallace, H., Clarke, A.R., Harrison, D.J., Hooper, M.L., and Bishop, J.O., 1996, Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis. Oncogene 13(1):55–61.PubMedGoogle Scholar
  79. Wands, I.R., and Blum, H.E., 1991, Primary hepatocellular carcinoma. New Engl. J. Med. 325:729–731.PubMedCrossRefGoogle Scholar
  80. Wang, X.W., Gibson, M.K., Vermeulen, W., Yeh, H., Forrester, K., Stürzbecher, H.-W., Hoeijmakers, J.H.J., and Harris, C.C., 1995, Abrogation of p53-induced apoptosis by the hepatitis B vris X gene. Cancer Res. 55:6012–6016.PubMedGoogle Scholar
  81. Weinberg, R.A., 1991, Tumour suppressor genes. Science 254:1138–1146.PubMedGoogle Scholar
  82. Weisburger, E., 1977, Carcinogenicity studies on halogenated hydrocarbons. Environ. Health Perspect 21:25–30.Google Scholar
  83. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC., 1996, Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 24(5):1264–1268.PubMedGoogle Scholar
  84. Yotsuyanagi, H., Koike, K., Yasuda, K., Moriya, K., Hino, K., Kurokawa, K., and Iino, S., 1995, Hepatitis C Virus Genotypes and Development of Hepatocellular Carcinoma. Cancer 76:1352–1355.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Ragai R. Mitry
    • 1
  • Marc R. Mansour
    • 1
  • Roman Havlik
    • 1
  • Nagy A. Habib
    • 1
  1. 1.Liver Surgery Section Division of Surgery Anaesthetics and Intensive CareImperial College School of MedicineLondonUK

Personalised recommendations